Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MADELEINE DUVIC and JONATHAN L CURRY.
Connection Strength

2.103
  1. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877.
    View in: PubMed
    Score: 0.171
  2. Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation. Pediatr Dermatol. 2018 Jan; 35(1):e13-e16.
    View in: PubMed
    Score: 0.153
  3. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176.
    View in: PubMed
    Score: 0.143
  4. Primary Cutaneous Gamma-Delta (?/d) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. Am J Dermatopathol. 2016 10; 38(10):e147-9.
    View in: PubMed
    Score: 0.141
  5. Verrucous presentation in patients with mycosis fungoides. Int J Dermatol. 2016 Mar; 55(3):e126-9.
    View in: PubMed
    Score: 0.133
  6. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61.
    View in: PubMed
    Score: 0.121
  7. Alopecia areata after HLA-identical BMT from an affected, sibling donor. Bone Marrow Transplant. 2014 Apr; 49(4):592-4.
    View in: PubMed
    Score: 0.117
  8. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014 Mar; 41(3):326-8.
    View in: PubMed
    Score: 0.117
  9. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84.
    View in: PubMed
    Score: 0.113
  10. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8.
    View in: PubMed
    Score: 0.110
  11. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol. 2013 Sep; 52(9):1111-4.
    View in: PubMed
    Score: 0.102
  12. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/S?zary syndrome. J Cutan Pathol. 2011 Mar; 38(3):295-7.
    View in: PubMed
    Score: 0.096
  13. The spectrum of hair loss in patients with mycosis fungoides and S?zary syndrome. J Am Acad Dermatol. 2011 Jan; 64(1):53-63.
    View in: PubMed
    Score: 0.094
  14. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides. Cells. 2024 Feb 27; 13(5).
    View in: PubMed
    Score: 0.059
  15. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders? Virchows Arch. 2021 Aug; 479(2):377-383.
    View in: PubMed
    Score: 0.048
  16. Differential expression of CCR4 in primary cutaneous gamma/delta (?/d) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. J Dermatol Sci. 2018 Jan; 89(1):88-91.
    View in: PubMed
    Score: 0.038
  17. Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (?d) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous ?d T-Cell Lymphomas. Am J Surg Pathol. 2017 Feb; 41(2):204-215.
    View in: PubMed
    Score: 0.036
  18. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 Dec; 43(12):1161-1166.
    View in: PubMed
    Score: 0.035
  19. ?Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell. 2016 06 13; 29(6):874-888.
    View in: PubMed
    Score: 0.035
  20. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016 Apr; 50:79-89.
    View in: PubMed
    Score: 0.033
  21. A case of indeterminate dendritic cell tumor presenting with leonine facies. J Cutan Pathol. 2016 Feb; 43(2):158-63.
    View in: PubMed
    Score: 0.033
  22. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.
    View in: PubMed
    Score: 0.031
  23. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol. 2014 Jan; 41(1):51-7.
    View in: PubMed
    Score: 0.029
  24. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife. 2013 Nov 05; 2:e00969.
    View in: PubMed
    Score: 0.029
  25. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol. 2014 Feb; 41(2):88-100.
    View in: PubMed
    Score: 0.029
  26. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther. 2014 Jan; 13(1):221-9.
    View in: PubMed
    Score: 0.029
  27. Pediatric subcutaneous panniculitis-like T-cell lymphoma with features of hemophagocytic syndrome. Pediatr Blood Cancer. 2013 Nov; 60(11):1916-7.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.